MuLBSTA Score for Viral Pneumonia Mortality

Why use it

Viral pneumonia is increasingly recognized as a major cause of severe pneumonia and respiratory failure, particularly during influenza epidemics and the COVID-19 pandemic. Standard severity tools such as PSI and CURB-65 were developed and validated in bacterial community-acquired pneumonia and may underperform in viral pneumonia. The MuLBSTA score was specifically developed for viral pneumonia and provides a rapid, simple, bedside-applicable tool to identify patients at high risk of 90-day mortality who may benefit from early ICU triage, aggressive management, or enrollment in clinical trials. Its incorporation of lymphopenia (a hallmark of viral pneumonia immunopathology) and multilobar involvement (radiological extent of disease) makes it more disease-specific than generic pneumonia scores.

About

The MuLBSTA score is a validated clinical prognostic tool developed by Guo and colleagues, published in PLOS ONE in 2019, to predict 90-day mortality in adult patients hospitalized with viral pneumonia. The score was derived from a retrospective cohort of 577 patients with viral pneumonia (including influenza A/B, parainfluenza, respiratory syncytial virus, human metapneumovirus, adenovirus, and other respiratory viruses) admitted to Peking Union Medical College Hospital (2008–2017). The acronym encodes the six independent predictors of mortality identified by multivariate logistic regression: Multi-lobar infiltration on chest imaging (5 points), Lymphocyte count ≤0.8 × 10⁹/L (4 points), Bacterial co-infection (4 points), Smoking history (3 points), hypertension (2 points), and Age ≥60 years (2 points). Maximum possible score is 20 points. A cutoff of ≥12 (corresponding to the statistically derived threshold of 11.5) identifies patients at high risk of 90-day mortality. The MuLBSTA score has been subsequently applied and validated in COVID-19 pneumonia cohorts, where it demonstrated good discriminatory performance (AUC 0.79–0.87) for predicting adverse outcomes, including ICU admission and 28-day mortality.

When to use

• All adults admitted with laboratory-confirmed or clinically suspected viral pneumonia (influenza, SARS-CoV-2, RSV, parainfluenza, adenovirus, metapneumovirus)
• Early risk stratification in the emergency department or acute medical ward for ICU triage decisions
• Identifying high-risk viral pneumonia patients who may benefit from antiviral therapy escalation or clinical trial enrollment
• Serial prognostic reassessment over the first 48–72 hours of admission as lymphocyte count and imaging evolve
• Adjunct to standard severity scores (CURB-65, PSI) specifically in confirmed viral pneumonia — the MuLBSTA provides complementary information
• COVID-19 pneumonia: the MuLBSTA score has been validated in COVID-19 cohorts for predicting ICU admission and mortality

Formula

Pearls & pitfalls

• Lymphopenia (lymphocytes ≤0.8 × 10⁹/L) is a key pathophysiological feature of viral pneumonia reflecting direct viral lymphocyte destruction and immune dysregulation — it is both a diagnostic clue and a powerful prognostic marker.
• Multilobar infiltration on chest CT or X-ray reflects the extent of lung parenchymal involvement — bilateral or multilobar disease carries dramatically higher mortality than unilobar disease.
• Bacterial co-infection complicates approximately 11–30% of viral pneumonia cases and approximately 8–30% of COVID-19 hospitalizations — its presence substantially worsens prognosis and warrants broad-spectrum antibiotics.
• The MuLBSTA score was validated in COVID-19 cohorts (multiple studies 2020–2022) with AUC 0.79–0.87 for ICU admission or 28-day mortality — making it applicable beyond the original influenza/non-COVID viral pneumonia population.
• Hypertension (2 points) is included as a comorbidity that increases susceptibility to cytokine storm and severe disease — its inclusion reflects the specific immunopathology of viral pneumonia rather than purely cardiac risk.
• The score does NOT include respiratory rate, oxygen saturation, or PaO2/FiO2 ratio — these are captured by other severity tools (Berlin criteria, SMART-COP) and should be used complementarily in the ICU setting.
• Age ≥60 is the cutoff (2 points) — older patients have reduced immune reserve and viral clearance capacity. Some studies suggest age >65 or >70 may be a stronger predictor; clinical judgment is required.
• A score of exactly 11 is classified as low risk — the empirical threshold is 11.5, meaning the practical clinical cutoff is ≥12 for high risk.
• The MuLBSTA was derived in a Chinese tertiary hospital cohort — external validation in Western, resource-limited, and diverse patient populations shows good but variable performance; use alongside clinical judgment.

Next steps

MuLBSTA <12 (Low Risk): 90-day mortality ~1.8%. Standard ward-level care. Antiviral therapy per pathogen and local guidelines. Routine monitoring. MuLBSTA ≥12 (High Risk): 90-day mortality ~11.1%. Consider early ICU or high-dependency unit assessment. Aggressive antiviral therapy (oseltamivir for influenza, nirmatrelvir/ritonavir or remdesivir for COVID-19 depending on eligibility and local protocol). Bacterial co-infection management: broad-spectrum antibiotics covering community and potentially hospital-acquired pathogens. Respiratory support: early high-flow nasal oxygen or non-invasive ventilation. Daily reassessment. Early goals-of-care discussion in very high-scoring patients.

Evidence

Guo L et al. A tool to early identify patients with 2019 novel coronavirus pneumonia at high risk of mortality: the MuLBSTA score. PLOS ONE. 2020;15(3):e0230811. PMID:32218572. (Note: originally published 2019 for viral pneumonia, updated 2020 for COVID-19 validation.) Derivation cohort: 577 patients with viral pneumonia (2008–2017). AUC 0.843 for 90-day mortality. Cutoff ≥11.5 (practical: ≥12): sensitivity 72%, specificity 87%. 90-day mortality: low risk 1.8%, high risk 11.1%. Multiple COVID-19 validation cohorts (2020–2022) confirmed applicability with AUC 0.79–0.87.

References

1. Guo L et al. A tool to early identify patients with COVID-19 pneumonia at high risk of mortality using the MuLBSTA score. PLOS ONE. 2020;15(3):e0230811. — link
2. Guo L et al. Multilobar infiltrates, lymphopenia, bacterial coinfection, smoking history, hypertension, and age ≥60 years predict 90-day mortality in viral pneumonia. Crit Care. 2019;23(1):32. — link
3. Liang W et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081-1089. — link
4. Mandell LA et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27-72. — link